Condition (MeSH)
Serotonin Syndrome
ClinicalTrials.gov lists 35 trials for Serotonin Syndrome or a narrower condition beneath it. Lexicon Pharmaceuticals has the most among industry and government lead sponsors, with 6.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
35 of the 35 trials are tagged with Serotonin Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Serotonin Syndrome trials start? (17)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2022 | 3 |
| 2021 | 4 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 2 |
| 2017 | 1 |
| 2016 | 1 |
| 2015 | 2 |
Showing 10 of 17 earlier years.
No forecast is made for this condition: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Serotonin Syndrome trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 1 |
| Phase 2 | 13 |
| Phase 3 | 8 |
| Phase 4 | 1 |
| Not applicable | 2 |
| Observational | 8 |
How many Serotonin Syndrome trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 1 |
| Active, not recruiting | 2 |
| Completed | 18 |
| Terminated | 5 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Serotonin Syndrome trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Lexicon Pharmaceuticals | 6 |
| Ipsen | 4 |
| Crinetics Pharmaceuticals Inc. | 2 |
| Camurus AB | 1 |
| Endo USA Inc., a Keenova Therapeutics Company | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Serotonin Syndrome? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Telotristat Etiprate | 7 |
| Telotristat Ethyl | 3 |
| Cyproheptadine | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| LAR Octreotide | 2 |
| LAR Lanreotide | 2 |
| 500 mg [14C]-LX1606 | 1 |
| Randomized: 80 mg Paltusotine | 1 |
| Lutetium-177 DOTATATE | 1 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Serotonin Syndrome trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Disease progression | 18 | 4 |
| Small intestinal obstruction | 11 | 5 |
| Abdominal pain | 9 | 3 |
| Investigation | 9 | 2 |
| Neuroendocrine tumour | 8 | 3 |
Showing 5 of 10 adverse events.
Which publications cover Serotonin Syndrome? (11)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| 5-Hydroxytryptophan (5-HTP): Natural Occurrence, Analysis, Biosynthesis, Biotechnology, Physiology and Toxicology. | International journal of molecular sciences | 2020 | Yes |
| Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis. | Clinical therapeutics | 2016 | Yes |
| Tramadol, Pharmacology, Side Effects, and Serotonin Syndrome: A Review. | Pain physician | 2015 | Yes |
| Serotonin syndrome in a patient taking Lexapro and Flexeril: a case report. | The American journal of emergency medicine | 2008 | Yes |
| Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2006 | Yes |
Showing 5 of 11 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Serotonin syndrome | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Serotonin syndrome | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Serotonin syndrome | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Serotonin syndrome | 43116 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Serotonin syndrome | 43116 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.